Autoimmune Flare after Receiving Chemotherapy in Hematological Malignancies; A Case Series and Review of Literature

Jhanzeb Iftikhar; Fareeha  Sheikh; Syed Abdul Mannan  Hamdani; Musa  Azhar; Shafquat Ali  Khan; Bushra  Ahsan

doi:10.51253/pafmj.v75iSUPPL-2.6117

Authors

Jhanzeb Iftikhar Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Pakistan
Fareeha Sheikh Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Pakistan
Syed Abdul Mannan Hamdani Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Pakistan
Musa Azhar Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Pakistan
Shafquat Ali Khan Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Pakistan
Bushra Ahsan Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75iSUPPL-2.6117

Keywords:

Autoimmune Disease, Flare, Lymphoma, Outcome

Abstract

Lymphoma and autoimmune diseases may share common predisposing factors. The clinical features of lymphoma patients presenting with autoimmune conditions are scarcely reported. It has been shown in some previous studies that the probability of lymphoma development may be increased on the background of autoimmune diseases. However, whether autoimmune diseases worsen the outcomes for lymphoma patients remains ambiguous. We present a case series of 3 lymphoma patients in which a rare phenomenon of autoimmune flare was noticed after receiving chemotherapy.

Downloads

References

- Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders–what are the driving forces? InSeminars in cancer biology 2014: 24: 61-70.

- Van den Bergh M, Alvarez-Argote J, Panwala AH, Dasanu CA. Autoimmune disorders in patients with T-cell lymphoma: a comprehensive review. Curr Med Res Opin 2015; 31(10): 1861-1870.

- Hellgren K, Baecklund E, Backlin C, Sundstrom C, Smedby KE, Askling J. Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheumatol 2017; 69(4): 700-708.

- Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Med 2016; 95(25).

- Váróczy L, Páyer E, Kádár Z, Gergely L, Miltényi Z, Magyari F, et al. Malignant lymphomas and autoimmunity—a single center experience from Hungary. Clin Rheumatol 2012; 31(2): 219-224.

- Löfström B, Backlin C, Pettersson TO, Lundberg IE, Baecklund E. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. The Journal of rheumatology 2011; 38(9): 1891-1897.

- Papageorgiou A, Ziogas DC, Mavragani CP, Zintzaras E, Tzioufas AG, Moutsopoulos HM, et al. Predicting the outcome of Sjogren’s syndrome-associated non-Hodgkin’s lymphoma patients. PloS one 2015; 10(2): e0116189.

- Hollander P, Rostgaard K, Smedby KE, Chang ET, Amini RM, de Nully Brown P, et al. Autoimmune and atopic disorders and risk of classical Hodgkin lymphoma. American journal of epidemiology 2015; 182(7): 624-632.

- Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmunity reviews 2017; 16(10): 1049-1057.

- Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Archives of internal medicine 2005; 165(20): 2337-2344.